Evidence map›Paper›PMID 42395864›Full record

ArticleNAR genomics and bioinformatics2026

asms: finding allele-specific methylation in human genomes without phasing.

Emanuele Raineri, Miguel Ángel Esteve Marco, Eloi Casals, Anna Esteve Codina

Abstract read
In one paragraph

Article in NAR genomics and bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Emanuele RaineriCentro Nacional de Análisis Genómico (CNAG), Baldiri Reixac 4, 08028 Barcelona, Spain.ORCID https://orcid.org/0000-0003-1932-311X
Miguel Ángel Esteve MarcoUniversitat Oberta de Catalunya (UOC), Rambla del Poblenou, 156, 08018 Barcelona, Spain.
Eloi CasalsCentro Nacional de Análisis Genómico (CNAG), Baldiri Reixac 4, 08028 Barcelona, Spain.
Anna Esteve CodinaCentro Nacional de Análisis Genómico (CNAG), Baldiri Reixac 4, 08028 Barcelona, Spain.ORCID https://orcid.org/0000-0003-0361-2873

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allele-specific methylation (ASM) refers to the differential DNA methylation between two alleles at a specific locus. This phenomenon can be driven by genomic imprinting (where gene expression depends on the parent of origin) or by genetic variants (that may affect DNA-protein binding), both of which play crucial roles in gene regulation and contribute to normal biological variation and disease. ASM can be tissue- or cell-type specific, which adds an extra layer of complexity to its analysis. Detection methods typically rely on phasing using genetic variants, a process that is computationally intensive and can fail in regions with low heterozygosity. To overcome these limitations, we developed asms (Allele-Specific Methylation Scanner), a tool that identifies potential ASM loci from methylation data without requiring prior phasing by looking at heterogeneous methylation across reads. Although we tested it using Oxford Nanopore Technologies (ONT) data, the tool can be used with any platform using MM/ML tags to store methylation in BAM files. asms can examine efficiently thousands of loci (either from a list or through an automatic genomic scan) by segregating reads based on their methylation patterns. When information on variants is available, asms can verify whether distinct alleles correspond to different base modification profiles. asms is available at https://github.com/ecmra/asms.

Indexed as

AllelesDNA MethylationGenome, HumanSoftwareGenomic ImprintingHumans

Identifiers

PMID42395864
PMCPMC13326645

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.